Jenscare Scientific Co., Ltd., a medical device company, engages in the research and development of interventional products for the treatment of structural heart diseases in the People’s Republic of China. It offers LuX-Valve and LuX-Valve Plus, a transcatheter tricuspid valve replacement (TTVR) product for the treatment of severe tricuspid regurgitation and high surgical risk; KenFlex, a transcatheter aortic valve intervention (TAVR) repair system product for the treatment of aortic valve regurgitation; and Ken-Valve, a TRVR system for the treatment of severe aortic regurgitation or combined with aortic stenosis. The company also develops JensClip, a clip-based transcatheter mitral valve intervention (TMVR) repair system to treat patients with severe mitral regurgitation; JensRelive, a TMVR system to treat patients with severe mitral regurgitation and replace dysfunctional primary mitral valves without undergoing routine thoracotomy surgery; and SimuLock, a bionics left atrial appendage occluder system for cardiogenic stroke prevention. In addition, it offers platform technologies/accessories comprising introducer kit, JeniGal anti-calcification technology, dry-tissue technology and polymer leaflet technology; and engages in consulting and investment activities.